Of All Places

On page B1 of the 9-10-12 Business Page of The New York Times Duff Wilson has written an article
about the disagreement advisory board officials are having with each other and with the FDA about
what sort of labelling to put on osteoporosis medicines.
Apparently the FDA doesn't find evidence of advantage in using these longer than five years.
That's too bad, because old age brings enough challenges without the threat of being more bent than
is absolutely necessary, right?
Apparently, a relatively small number of long term users will suffer unusual thigh fractures, or serious
jaw disease.
Doctors who are weighing the risks and benefits of the medicines effects relative to a patients'  overall health landscape, cannot agree on the severity of keeping to the medicinal regime versus
stopping after a few years.
Dr. Jennifer P. Schneider's thigh broke as she stood in a New York subway. Now that's scary!
Dr. Schneider has herself studied both osteoporosis and osteopenia.
Osteopenia is a post osteoporosis condition.
As I am not looking forward to having more bone problems than I already have, I sure hope they come up with something soon.
Why was this article on page 1 of the Business Section?
Worldwide sales of these drugs last year was $7.6 billion.
So many of us are getting older so quickly now.